<DOC>
	<DOCNO>NCT01336608</DOCNO>
	<brief_summary>The purpose study investigate effect fluticasone furoate/vilanterol Inhalation Powder arterial stiffness compare placebo vilanterol 24-week treatment period subject COPD aortic pulse wave velocity 11.0 m/s .</brief_summary>
	<brief_title>A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>COPD diagnosis define ATS/ERS Former current smoker A measure aortic pulse wave velocity = &gt; 11.0 m/s Screening Pregnancy A current diagnosis asthma alpha1antitrypsin deficiency underlie cause COPD subject active respiratory disorder A cardiovascular event occur 6 month prior Visit 1 Current severe heart failure ( New York Heart Association Class IV ) know ejection fraction &lt; 30 % Clinical significant uncontrolled hypertension Abnormal clinical significant 12lead ECG finding Visit 1 Have lung volume reduction lung transplantation within 12 month prior Visit 1 Poorly control COPD : Acute worsen COPD manage subject antibiotic corticosteroid , require treatment prescribed physician 6 week prior Visit 1 ; subject need hospitalise due poorly control COPD within 12 week prior Visit 1 Lower respiratory tract infection require use antibiotic within 6 week prior Visit 1 Participate acute phase pulmonary rehabilitation within 4 week prior Visit 1 enter acute phase pulmonary rehabilitation study . Other disease abnormality opinion investigator would put safety subject risk participation ; would affect safety efficacy analysis disease/condition exacerbate study . subject carcinoma complete remission least 5 year . Carcinoma site cervix , squamous cell carcinoma basal cell carcinoma skin would exclude subject consider cure within 5 year since diagnosis . subject history hypersensitivity study medication component inhalation powder . subject know suspected history alcohol drug abuse within last 2 year prior Screening subject medically unable withhold albuterol ipratropium 4 hour prior spirometry test study visit subject medically unable stop 'excluded medication ' list protocol subject start , discontinue certain medication list protocol stable dose past three month prior Screening , anticipate remain stable dose study treatment period . Long term oxygen therapy require &gt; 12 hour per day flow rate &gt; 2 L/min A body mass index = &gt; 35 kg/m2 Fasting lipid level LDL &gt; 3.3 mmol/L , total cholesterol &gt; 5.2 mmol/L , triglycerides &gt; 2.24mmol/L Noncompliance Questionable validity consent Prior use study medication investigational drug . Affiliation investigator site</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>